礼来关于公共卫生抗体药物临床试验将中止
© Reuters. 礼来(LLY.US)关于公共卫生抗体药物临床试验将中止
智通财经APP获悉，目前礼来公司 (NYSE:LLY)在医院进行的针对公共卫生事件的治疗实验将会结束。
据悉，该实验疗法对于帮助公共卫生事件患者康复的可能性有待商榷；因此将不会再有公共卫生事件患者接受礼来的Bamlanvimab抗体药物治疗，但是目前公司其他所有关于Bamlanvimab的研究仍然在进行当中。
而日前，美国国立卫生研究院的过敏与传染病研究所（NIAID）还暂停了礼来关于中和抗体药物的ACTIV-3临床试验。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
If you like, reward to support.
Hot
No comment on record. Start new comment.